Zealand Pharma A/S (OTCMKTS:ZLDPF) Shares Up 9.1% – Still a Buy?

Zealand Pharma A/S (OTCMKTS:ZLDPF)’s share price shot up 9.1% during mid-day trading on Monday . The stock traded as high as $44.71 and last traded at $44.71. 500 shares changed hands during trading, a decline of 90% from the average session volume of 4,843 shares. The stock had previously closed at $40.99.

Analysts Set New Price Targets

A number of equities analysts have issued reports on ZLDPF shares. BNP Paribas Exane downgraded shares of Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a report on Friday, March 6th. Cantor Fitzgerald reissued a “neutral” rating on shares of Zealand Pharma A/S in a research report on Friday, March 6th. Deutsche Bank Aktiengesellschaft restated a “hold” rating on shares of Zealand Pharma A/S in a report on Tuesday, December 16th. Finally, William Blair reiterated a “market perform” rating on shares of Zealand Pharma A/S in a research note on Friday, March 6th. Three investment analysts have rated the stock with a Strong Buy rating and five have assigned a Hold rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy”.

Zealand Pharma A/S Stock Up 0.6%

The stock has a 50 day moving average price of $56.07 and a 200 day moving average price of $67.96. The company has a debt-to-equity ratio of 0.02, a quick ratio of 23.57 and a current ratio of 23.57. The company has a market capitalization of $3.18 billion, a P/E ratio of 3.27 and a beta of 0.76.

Zealand Pharma A/S (OTCMKTS:ZLDPF) last announced its quarterly earnings data on Thursday, February 19th. The company reported ($0.81) EPS for the quarter, topping the consensus estimate of ($1.34) by $0.53. Zealand Pharma A/S had a net margin of 70.06% and a return on equity of 48.10%. The business had revenue of $10.79 million for the quarter, compared to analyst estimates of $19.69 million. Equities research analysts forecast that Zealand Pharma A/S will post -2.19 earnings per share for the current fiscal year.

About Zealand Pharma A/S

Zealand Pharma A/S is a Denmark‐based biopharmaceutical company specializing in the discovery, design and development of peptide‐based therapeutics. Utilizing proprietary peptide engineering platforms, the company focuses on metabolic and endocrine disorders, including diabetes and rare gastrointestinal diseases. Zealand employs a rational design approach to optimize stability, selectivity and dosing profiles of its candidates, aiming to improve patient outcomes where current treatment options are limited.

Among the most advanced assets in Zealand’s pipeline is dasiglucagon, a stable glucagon analog designed for the emergency treatment of severe hypoglycemia.